<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00901394</url>
  </required_header>
  <id_info>
    <org_study_id>09-0074</org_study_id>
    <nct_id>NCT00901394</nct_id>
  </id_info>
  <brief_title>Vitamin B12 and Folate Administration on Homocysteine Concentrations After Nitrous Oxide Anesthesia</brief_title>
  <acronym>Mini-VINO</acronym>
  <official_title>Influence of Preoperative Vitamin B12 and Folate Administration on Homocysteine Concentrations After Nitrous Oxide Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation for Anesthesia Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to find out if giving intravenous B-vitamins before general&#xD;
      anesthesia with nitrous oxide prevents the increase in homocysteine, a metabolite that has&#xD;
      been linked to cardiovascular complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized into the following arms:&#xD;
&#xD;
        -  Arm A: patients will receive N2O (60% N2O/40% O2) in an open-label fashion during&#xD;
           surgery and vitamin supplementation (vitamin B12, 1 mg, and folate, 5 mg) before&#xD;
           surgery.&#xD;
&#xD;
        -  Arm B: patients will receive N2O 60% N2O/40% O2) in an open-label fashion during surgery&#xD;
           and placebo before and after surgery.&#xD;
&#xD;
        -  Arm C: patients will not receive N2O, vitamin supplementation, or placebo during/before&#xD;
           surgery. Patients in this arm will not be randomized.&#xD;
&#xD;
      Patients will have blood drawn (total of 1-2 teaspoons over 3 days). We will take these&#xD;
      samples before their surgery, when their surgery is completed, and in the morning of&#xD;
      post-operative day 1. We will be checking their troponin I and troponin T, homocysteine,&#xD;
      Vitamin B12, and folate levels. We will also perform a 12-lead EKG. Before and after surgery&#xD;
      for patients in Arm A or B, will receive either vitamin B12 (1 mg) and folic acid (5 mg) (or&#xD;
      placebo) added to their IV infusion. We also plan to use a non-invasive test known as a nerve&#xD;
      conduction study to measure the function of their nerve system. Briefly, 2 small electrodes&#xD;
      are attached to their skin over a nerve and, like an EKG, faint electrical pulses are&#xD;
      generated and recorded. A typical nerve conduction measurement lasts about 10 minutes.&#xD;
&#xD;
      After the patients surgery we will do genetic testing of MTHFR genotype.&#xD;
&#xD;
      All study samples have been collected.&#xD;
&#xD;
      Of note: there were no secondary outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Plasma Total Homocysteine Concentration (tHcy)</measure>
    <time_frame>Immediately postoperatively and on postoperative day 1</time_frame>
    <description>Difference between baseline (pre-operative) and peak postoperative (i.e., maximum of postoperative value obtained within 30 minutes after anesthesia end time and morning of post-operative day 1) tHcy concentration .&#xD;
Of note: there were no secondary outcomes.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Cardiovascular Abnormalities</condition>
  <arm_group>
    <arm_group_label>Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B12-Folic acid, nitrous oxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nitrous oxide (NO) and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oxygen nitrogen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B12-Folic Acid, nitrous oxide</intervention_name>
    <description>IV vitamin B12 (cyanocobalamin) 1 mg, single administration over 30 min.&#xD;
IV folic acid, 5 mg, single administration over 30 min.&#xD;
Both diluted in 250 ml normal saline.</description>
    <arm_group_label>Treatment 1</arm_group_label>
    <other_name>b supplements</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrous oxide (NO) and placebo</intervention_name>
    <description>60% nitrous oxide anesthesia plus saline</description>
    <arm_group_label>Treatment 1</arm_group_label>
    <arm_group_label>Treatment 2</arm_group_label>
    <other_name>nitrous oxide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Treatment 2</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>oxygen nitrogen</intervention_name>
    <description>60% air and oxygen mix.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>air</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients scheduled for elective surgery with expected duration &gt; 2 hours&#xD;
&#xD;
          -  Healthy patients undergoing moderate surgery where the use of N2O is unproblematic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication against N2O (pneumothorax, mechanical bowel obstruction, middle ear&#xD;
             occlusion, laparoscopic surgery, raised intracranial pressure)&#xD;
&#xD;
          -  Patients requiring supplemental oxygen&#xD;
&#xD;
          -  Urgent or emergent surgery&#xD;
&#xD;
          -  Patients with vitamin B12 or folate deficiency or megaloblastic anemia&#xD;
&#xD;
          -  Patients with seizure disorder (epilepsy)&#xD;
&#xD;
          -  Allergy or hypersensitivity against IV cobalamin or folate&#xD;
&#xD;
          -  Patients with Leber's disease (hereditary optic nerve atrophy)&#xD;
&#xD;
          -  Patients taking supplemental vitamin B12 or folate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Nagele, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nagele P, Zeugswetter B, Wiener C, Burger H, Hüpfl M, Mittlböck M, Födinger M. Influence of methylenetetrahydrofolate reductase gene polymorphisms on homocysteine concentrations after nitrous oxide anesthesia. Anesthesiology. 2008 Jul;109(1):36-43. doi: 10.1097/ALN.0b013e318178820b.</citation>
    <PMID>18580170</PMID>
  </reference>
  <reference>
    <citation>Nagele P, Zeugswetter B, Eberle C, Hüpfl M, Mittlböck M, Födinger M. A common gene variant in methionine synthase reductase is not associated with peak homocysteine concentrations after nitrous oxide anesthesia. Pharmacogenet Genomics. 2009 May;19(5):325-9. doi: 10.1097/FPC.0b013e328328d54c.</citation>
    <PMID>19339913</PMID>
  </reference>
  <reference>
    <citation>Myles PS, Chan MT, Kaye DM, McIlroy DR, Lau CW, Symons JA, Chen S. Effect of nitrous oxide anesthesia on plasma homocysteine and endothelial function. Anesthesiology. 2008 Oct;109(4):657-63. doi: 10.1097/ALN.0b013e31818629db.</citation>
    <PMID>18813045</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 8, 2009</study_first_submitted>
  <study_first_submitted_qc>May 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <results_first_submitted>April 23, 2018</results_first_submitted>
  <results_first_submitted_qc>August 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2020</results_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nitrous oxide</keyword>
  <keyword>cobalamin</keyword>
  <keyword>homocysteine</keyword>
  <keyword>vitamin B12</keyword>
  <keyword>folate</keyword>
  <keyword>No specific diseases targeted</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Abnormalities</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Nitrous Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>63 patients were consented however only 59 were analyzed.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>B-vitamins Plus Nitrous Oxide</title>
          <description>IV vitamin B12 (cyanocobalamin) 1 mg,&#xD;
IV folic acid, 5 mg,&#xD;
60% nitrous oxide</description>
        </group>
        <group group_id="P2">
          <title>Nitrous Oxide Plus Placebo</title>
          <description>60% nitrous oxide&#xD;
Placebo: normal saline (no vitamins)</description>
        </group>
        <group group_id="P3">
          <title>Nitrous Oxide-free Group Plus Placebo</title>
          <description>No nitrous oxide during anesthesia (oxygen/nitrogen)&#xD;
Placebo: normal saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>B-vitamins Plus Nitrous Oxide</title>
        </group>
        <group group_id="B2">
          <title>Nitrous Oxide Plus Placebo</title>
        </group>
        <group group_id="B3">
          <title>Nitrous Oxide-free Group Plus Placebo</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="13"/>
                    <measurement group_id="B2" value="40" spread="14"/>
                    <measurement group_id="B3" value="42" spread="15"/>
                    <measurement group_id="B4" value="41" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Plasma Total Homocysteine Concentration (tHcy)</title>
        <description>Difference between baseline (pre-operative) and peak postoperative (i.e., maximum of postoperative value obtained within 30 minutes after anesthesia end time and morning of post-operative day 1) tHcy concentration .&#xD;
Of note: there were no secondary outcomes.</description>
        <time_frame>Immediately postoperatively and on postoperative day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1</title>
            <description>B12-Folic acid, nitrous oxide&#xD;
B12-Folic Acid, nitrous oxide: IV vitamin B12 (cyanocobalamin) 1 mg, single administration over 30 min.&#xD;
IV folic acid, 5 mg, single administration over 30 min.&#xD;
Both diluted in 250 ml normal saline.&#xD;
Nitrous oxide (NO) and placebo: 60% nitrous oxide anesthesia plus saline</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2</title>
            <description>Nitrous oxide (NO) and placebo&#xD;
Nitrous oxide (NO) and placebo: 60% nitrous oxide anesthesia plus saline&#xD;
Placebo: Saline</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>oxygen nitrogen&#xD;
Placebo: Saline&#xD;
oxygen nitrogen: 60% air and oxygen mix.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Total Homocysteine Concentration (tHcy)</title>
          <description>Difference between baseline (pre-operative) and peak postoperative (i.e., maximum of postoperative value obtained within 30 minutes after anesthesia end time and morning of post-operative day 1) tHcy concentration .&#xD;
Of note: there were no secondary outcomes.</description>
          <units>mcmol/L</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.2" upper_limit="3.6"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.6" upper_limit="4.8"/>
                    <measurement group_id="O3" value="0.5" lower_limit="-0.8" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For baseline comparisons among the three groups, one-way ANOVA was used for normally distributed variables and χ2 goodness-of-fit for categorical variables. To model the effects of B-vitamin treatment on nitrous-oxide-induced total homocysteine increase at the three different timepoints within individual patients and between the three groups, a linear mixed model with was used and we included a group × time interaction in the model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were assessed only in the immediate study period (surgery to postoperative day 1)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>B-vitamins Plus Nitrous Oxide</title>
        </group>
        <group group_id="E2">
          <title>Nitrous Oxide Plus Placebo</title>
        </group>
        <group group_id="E3">
          <title>Nitrous Oxide-free Group Plus Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Postop. cardiac troponin elevation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>PONV</sub_title>
                <description>Postopertaive nausea and vomiting</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Investigator</name_or_title>
      <organization>University of Chicago</organization>
      <phone>7737022544</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

